Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.
  • TickerSOBI
  • ISINSE0000872095
  • ExchangeNasdaq Nordic Stockholm
  • SectorPharmaceuticals & Biotechnology
  • CountrySweden

Analysts

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - EAHAD 2020 – our takeaways

We attended one of the largest haemophilia conferences Gene therapy unlikely to be a near-term threat to Sobi… …but docs are growing more comfortable with Hemlibra

Alexander Aukner ...
  • Eivind Sars Veddeng
  • Håkon Astrup
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Nicolay Dyvik
  • Niklas Wetterling
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Viktor Trollsten

Northern Lights

Patrik Ling

Swedish Orphan Biovitrum (Buy, TP: SEK275.00) - Gearing up for future growth

Sobi delivered a strong Q4, in line with expectations, with 2019 revenues of SEK14.3bn and adj. EBITA of SEK6.2bn. For 2020, we have tweaked our top-line estimate to SEK15.5bn, but have cut our EBITA forecast by c6%, given the increased investments in commercial and R&D in 2020e needed for future growth. We reiterate our BUY and SEK275 target price.

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - Management optimistic about acquired products

No surprises on Q4 earnings Broader 2020 guidance range indicates uncertainty Acquired products – the proof is in the pudding, HOLD

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - Q4’19 and 2020 outlook

Q4 results – no surprise as expected Guidance for 2020 What to do with the share today?

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - EAHAD 2020 – our takeaways

We attended one of the largest haemophilia conferences Gene therapy unlikely to be a near-term threat to Sobi… …but docs are growing more comfortable with Hemlibra

Patrik Ling

Swedish Orphan Biovitrum (Buy, TP: SEK275.00) - Gearing up for future growth

Sobi delivered a strong Q4, in line with expectations, with 2019 revenues of SEK14.3bn and adj. EBITA of SEK6.2bn. For 2020, we have tweaked our top-line estimate to SEK15.5bn, but have cut our EBITA forecast by c6%, given the increased investments in commercial and R&D in 2020e needed for future growth. We reiterate our BUY and SEK275 target price.

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - Management optimistic about acquired products

No surprises on Q4 earnings Broader 2020 guidance range indicates uncertainty Acquired products – the proof is in the pudding, HOLD

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - Q4’19 and 2020 outlook

Q4 results – no surprise as expected Guidance for 2020 What to do with the share today?

Rickard Anderkrans ...
  • Viktor Sundberg

Swedish Orphan Biovitrum - Q4 Eloctate sales continues downhill in the US

Q4’19 US Eloctate sales -25.6% y-o-y Stronger than expected royalties for Sobi… … but the market likely to focus on US figures

2 directors bought/maiden bought

Two Directors at Swedish Orphan Biovitrum Ab bought/maiden bought 16,500 shares at between 178.050SEK and 179.850SEK. The significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is...

Alexander Aukner ...
  • Eivind Sars Veddeng
  • Håkon Astrup
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Nicolay Dyvik
  • Niklas Wetterling
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Viktor Trollsten

Northern Lights

Christoffer Wang Bjørnsen ...
  • Helene Kvilhaug Brøndbo
  • Jimi Lehtonen
  • Joachim Gunell
  • Marius Knudssøn
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Patrik Ling
  • Paul Harper
  • Stefan Gauffin

Northern Lights

Eivind Sars Veddeng ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Jimi Lehtonen
  • Jon Berggren
  • Marius Knudssøn
  • Martin Huseby Karlsen
  • Nicolai Farstad Olsen
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Jon Berggren ...
  • Karl-Johan Bonnevier
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Joachim Gunell ...
  • Jon Berggren
  • Martin Arnell
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Paul Harper
  • Simen Mortensen

Northern Lights

With a more favourable environment, SWED.ORPHAN BIOVITRUM AB improves to Slightly Positive

SWED.ORPHAN BIOVITRUM AB (SE), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date July 2, 2019, the closing price was SEK 182.70 and its potential was estimated at SEK 218.37.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Swedish Orphan Biovitrum AB – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights Sweden

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

The U.S. has continued to separate itself from broad emerging market and developed international indexes. Thankfully, one positive is that MSCI EM and MSCI EAFE have been able to stabilize from a price perspective despite relative strength weakness vs. MSCI ACWI... see charts below. In today's report we scour the globe for attractive investments in an environment where selectivity is key. • Emerging markets. There is still not much to like about broad EM as the MSCI Emerging Markets index has remained weak following price and relative strength breakdowns. Remain underweight broad EM and be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch